Federal judge pauses Covid-19 patent lawsuit trial against Pfizer, BioNTech
A federal judge has ruled that Moderna’s lawsuit against Pfizer and BioNTech will be put on hold, while the US Patent and Trademark Office reviews petitions brought against two of the three Covid-19...
View ArticleGabrielle Union-Wade promotes self-advocacy at media agency health event
Actor and producer Gabrielle Union-Wade often turns to social media for health advice. Her message to healthcare and pharma marketers? Do better. Union-Wade took the stage at Publicis Health Media’s...
View ArticleGAO examines state PBM regulation as Congress weighs wider reforms
The Government Accountability Office put several states’ regulations around pharmacy benefit managers under a microscope, finding that states favor broad authority over PBMs, in a new report published...
View ArticleNovartis showcases Phase 3 data for Fabhalta in IgAN, announces priority review
Months after landing the first approval for the rare disease drug Fabhalta, Novartis is on track to potentially expand the label. The FDA has granted priority review for the use of Fabhalta in IgA...
View ArticleJ&J says Darzalex, Carvykti drive Q1 pharma sales growth while medtech looms...
Johnson & Johnson released its first quarter financial report Monday morning, highlighting a sales growth of 2.3% to $21.4 billion and touting an 8.3% growth in worldwide innovative medicine sales...
View ArticleBoehringer Ingelheim touts 10-year plan as it eyes overtaking Bayer as...
Boehringer Ingelheim put the spotlight on a pipeline ripe with milestones over the next decade during its full-year 2023 call with the press. Driven in part by the blockbuster success of its diabetes...
View ArticleMaternal mental health startup LunaJoy raises $4.2M
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) A Y Combinator-backed startup just raised fresh capital for its approach to maternal mental health care...
View ArticleMarketingRx roundup: Viatris taps former Moderna exec for commercial chief;...
New commercial chief at Viatris: Viatris named Corinne Le Goff as its new chief commercial officer on Monday. Le Goff comes from Imunon where she was CEO, but before that was chief commercial officer...
View ArticleIntra-Cellular on track for another Caplyta label expansion after positive...
Intra-Cellular Therapies’ Caplyta significantly improved symptoms in a late-stage major depressive disorder trial, marking a step in the drug’s journey to becoming a pipeline-in-a-pill. Atypical...
View ArticleTakeda’s new deal with Kumquat; IL-2 biotech raises $55M
Plus, news about Neurocrine Biosciences, Nxera Pharma, Voyager Therapeutics and Acorda Therapeutics: Takeda inks pact with Kumquat: The San Diego biotech will get up to $130 million in the near term...
View ArticleIn latest turn to autoimmune therapies, Cullinan nabs $280M to join lupus space
At Cullinan, immunology is quite literally the new oncology. The biotech announced Tuesday that it’s expanding its pipeline from cancer to include immunology and changing its name from Cullinan...
View ArticleClik here to view.
How drugmakers are handling new pressure to recycle plastic injection pens as...
On plastic chairs made from discarded obesity and diabetes drug pen injectors, Novo Nordisk is literally sitting on its blockbuster GLP-1 solution. The cafeteria in its newest site in Denmark is full...
View ArticleCharles River aims to use $500M to reduce animal testing
Contract developer and manufacturer Charles River Laboratories is hoping to reduce reliance on animal testing with a $500 million launch of its Alternative Methods Advancement Project. The $500 million...
View ArticleClik here to view.
J&J’s multiple myeloma therapies drive oncology business despite slow...
Johnson & Johnson defended slower-than-expected sales of Carvykti in the first quarter, with execs saying they expect sales of the cell therapy to accelerate in the second half of the year. The...
View ArticleSandoz's Humira biosimilar nabs significant market share thanks to CVS...
The nine biosimilars competing with AbbVie’s megablockbuster Humira have tried everything from exactly imitating the latest version of brand-name Humira to taking more than 80% off the list price. But...
View ArticleFDA hits Natco with warning letter over India facility, suspends product...
Manufacturer Natco Pharma was hit with a warning letter earlier this month over violations at its facility in the Indian state of Telangana, following an insufficient response to an FDA Form 483 last...
View ArticleClik here to view.
Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD,...
After seven months on the market, Regeneron’s Eylea HD is already making strides with ophthalmologists. According to Spherix Global Insights’ research, 81% of ophthalmologists who use Eylea HD to treat...
View ArticleSenate bill targeting WuXi won't affect federal spending, CBO says
A Senate bill that would blacklist Chinese biotech companies like WuXi AppTec from doing business in the US may not see a vote until after the election, if ever. But if it does, the Congressional...
View ArticleClik here to view.
AbbVie inks deal for Medincell's long-acting injectable platform worth up to...
AbbVie is betting more than $1.9 billion on a French biotech’s long-acting injectable technology. The deal gives Medincell $35 million upfront and up to $1.9 billion in milestones for the development...
View ArticleClik here to view.
Amylyx reveals full data that drove pivotal failure for ALS drug: #AAN24
Amylyx outlined the scope of its Phase 3 defeat, demonstrating the extent to which its now-withdrawn ALS drug Relyvrio failed to separate itself from placebo. In the primary endpoint measuring...
View Article